Kuldip Sra

A biopharma professional with more than 30 years’ experience in Vaccines, Cell therapy, Crispr Gene Editing and Vectors. Dr. Sra has worked on commercialization of 5 drug products’ and worked on submissions of over 15 INDs. Dr. Sra led Late-Stage Development at Crispr Therapeutics. At Kite/Gilead, Dr. Sra was head of QC Clinicals where he led assays development, validation and tech transfer of lot release analytical assays and BLA submission which helped in the successful U.S. licensure of Yescarta®, a first in class anti-CD19 CAR T cell therapy and subsequently also worked on Kite Pharma second licensed product Tecartus® for Mantle Cell Lymphoma. Dr. Sra worked over 15 years at MedImmune/Astra Zeneca in different capacities where he was involved in commercialization of three vaccine products.